Arcoma (ARCOMA) Q1 2026 earnings summary

Executive summary

• Q1 2026 saw an 11% year-over-year revenue decline to 31.1 MSEK, mainly due to delayed decisions in Europe and weaker Asian sales, while North America remained stable.

• EBITDA fell to 2.5 MSEK (8% margin), but profitability was maintained despite lower sales.

• The company retains a strong financial position with 33.9 MSEK in cash and no long-term debt.

• Focus is on accelerating growth, expanding sales channels, and product innovation.

Financial highlights

• Net sales: 31,131 KSEK, down from 34,875 KSEK year-over-year.

• EBITDA: 2,475 KSEK, down from 4,458 KSEK.

• EBIT: 935 KSEK, down from 2,587 KSEK.

• Net income: 811 KSEK, down from 2,044 KSEK.

• EPS: 0.06 SEK, down from 0.16 SEK.

• Gross margin: 40% vs. 43% prior year.

Outlook and guidance

• Positioned for growth with a scalable cost base and strong cash position.

• Plans to accelerate sales, continue product innovation, and leverage cost structure for higher profitability as volumes rise.